The board of directors, composed of seven members, is the Company´s decision-making body responsible for formulating general directives and business guidelines, including offering guidance on its long-term strategies.
The members are appointed for a period of two years and may be reelected. Decisions of the board of directors are adopted by a majority vote of the directors present or represented at such meeting.
- Co-founder of WM Partners, a private equity firm in health and wellness.
- Board member/investor in companies like Health Hero, Atida, Medneo GmbH, and Gauzy Ltd.
- Former CEO of CFR Pharmaceuticals, leading 15+ acquisitions, including Lafrancol S.A. in Colombia.
- Holds a degree in Business Administration from Universidad Católica de Chile; certified public auditor.
- President of Respark Residential, focused on real estate investments.
- Board member of Health Hero, Atida, Medneo GmbH, and NRS Agro.
- Former Chief of Marketing and Sales at CFR Pharmaceuticals.
- Holds a Master’s in Finance from Universidad Adolfo Ibáñez and an MBA from Kellogg School of Management.
- 20+years of experience in global healthcare and pharma companies with a successful track record in value-creating transactions, international business, strategic planning, and mergers and acquisitions of public and private companies
- Previously, served as Board Member of several private and listed companies, including CFR Pharmaceuticals S.A., Clínica Las Condes S.A. and Chairman of the Board of Laboratorio Chile S.A
- Master’s in Commercial Law from Duke University School of Law
- Chairman of the COMPENSATION COMMITTEE and member of the NOMINATING and AUDIT COMMITTEES.
- Mr. Carlos Garcia Iragorri has acted as an investor in various ventures since January 2020. He has over 30 years of senior-level pharmaceutical experience in Latin America and emerging markets.
- From April 2018 to January 2020, Mr. Garcia Iragorri served as Chief Executive Officer of Wellwaze, a Miami-based medical device startup focused on the early detection of breast cancer. Prior to this role, Mr. Garcia Iragorri served as the President of the Asia, Middle East, and Africa Regions for Novartis Pharmaceuticals, an international pharmaceutical company, for three years, and as the President of Latin America and Canada operations for twelve years.
- Between 1983 and 2002, Mr. Garcia Iragorri held various roles at Eli Lilly, an international pharmaceutical company, including President of Central and Eastern Europe, General Manager of Mexico, Argentina, and the Philippines, and CFO of the Colombian division. Additionally, from January 2018 to December 2021, Mr. Garcia Iragorri served as Chairman of the Board of Skalar Pharma, a pharmaceutical ingredient manufacturer.
- Mr. Garcia Iragorri holds an MBA from both Cornell University and Katholieke Universiteit te Leuven, as well as a degree in industrial engineering from Universidad del Norte.
- Mr. Vial is currently Chairman of the board of ABC S.A., a retail company that operates department stores within Chile, a position he has held since 2017.
- Chairman of the Board of CIC S.A., a mattress manufacturing and sales company, a position he has held since 2012.
- Director for Larrain Vial S.A., a global banking and financial services firm in Chile, a position he has held since 2019; and a Director for Santana S.A., an investment company, a position he has held since 2012.
- Mr. Vial holds a bachelor’s degree in law from Universidad de los Andes.
Mr. Romero-Camacho currently serves as Chief People & Corporate Affairs Officer at Insud Pharma Group, a global pharmaceutical group, a position that he has held since 2011, leading HR, Communication, Public Affairs, Internal Audit, and Compliance. Mr. Romero-Camacho has held senior positions in Human Resources and Legal Affairs across various roles and geographies in the pharmaceutical, automotive, and consumer sectors, in particular, at Renault Trucks, Bristol-Myers Squibb, and SmithKline Beecham. Mr. Romero-Camacho has served as a representative in public and private institutions and as coordinator of Fundación Mundo Sano in Spain. Mr. Romero Camacho holds a Law degree from UAM, an MBA from ICADE, and has completed the General Management Program at INSEAD.
Mr. Moreira Muniz currently serves as a Director and CEO of Urufarma, a pharmaceutical manufacturing company with a presence in Eastern Europe and Latin America, a position he has held since 2007. Mr. Moreira Muniz also currently serves as Secretary for the Association of National Laboratories in Uruguay, an organization that represents and supports national laboratories and promotes the development of the Uruguayan pharmaceutical industry. Prior to these roles, Mr. Moreira Muniz served as Deputy Manager for a Uruguayan branch of Banco Santander, a Spanish multinational financial services company. Mr. Moreira Muniz holds an MBA from the University of Montevideo, as well as a bachelor’s degree in international business from the Catholic University of Uruguay.